AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22545821 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 39
Study 22545821 — intervention group
Group type: EXPERIMENTAL
Intervention: NECT (exposed participants)
Number of subjects: 39
Study 22545821 — intervention group
Group type: EXPERIMENTAL
Intervention: NECT (unexposed participants)
Number of subjects: 39
Study 19930236 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing (BMI)
Number of subjects: 184
Study 19930236 — intervention group
Group type: COMPARATOR
Intervention: Information-advice (Control)
Number of subjects: 184
Study 17490978 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil (FO) supplementation (0.5 g DHA and 0.15 g EPA)
Number of subjects: 311
Study 17490978 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHF supplementation (400 microg methyltetrahydrofolic acid)
Number of subjects: 311
Study 17490978 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 311
Study 18160753 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C
Number of subjects: 84
Study 18160753 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg vitamin C
Number of subjects: 84
Study 15485474 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-coated stents
Number of subjects: 502
Study 15485474 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 502
Study 15485474 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 502
Study 15485474 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 502
Study 10829315 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy in combination with RO-resection
Number of subjects: 0
Study 10829315 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery alone
Number of subjects: 0
Study 8785149 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 0.06 mg kg‐1 i.v.
Number of subjects: 282
Study 8785149 — intervention group
Group type: EXPERIMENTAL
Intervention: prochlorperazine 0.2 mg kg‐1 i.m.
Number of subjects: 282
Study 8785149 — intervention group
Group type: COMPARATOR
Intervention: prochlorperazine 0.1 mg kg‐1 i.v.
Number of subjects: 282
Study 1356864 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 63
Study 1356864 — intervention group
Group type: COMPARATOR
Intervention: Secretin
Number of subjects: 63
Study 3886141 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin hydrochloride (50 mg during the first week, and 100 mg thereafter, at bedtime)
Number of subjects: 21
Study 3886141 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (1,200 mg/day in four divided doses)
Number of subjects: 21
Study 3886141 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin hydrochloride
Number of subjects: 21
Study 3886141 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 21
Study 3886141 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin hydrochloride and Cimetidine
Number of subjects: 21
Study 30318393 — intervention group
Group type: EXPERIMENTAL
Intervention: saline + NE (5 μg/min)
Number of subjects: 24
Study 30318393 — intervention group
Group type: EXPERIMENTAL
Intervention: phentolamine + NE (2.5 mg/min)
Number of subjects: 24
Study 30318393 — intervention group
Group type: COMPARATOR
Intervention: saline + saline
Number of subjects: 24
Study 28280053 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels measured in patients with eGFR 60-89 mL/min/1.73 m2
Number of subjects: 4372
Study 28280053 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels measured in patients with more advanced renal disease
Number of subjects: 4372
Study 28280053 — intervention group
Group type: COMPARATOR
Intervention: Copeptin levels measured in patients with normal renal function
Number of subjects: 4372
Study 27129606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 40
Study 27129606 — intervention group
Group type: COMPARATOR
Intervention: Intranasal midazolam
Number of subjects: 40
Study 24853591 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) - Hyalgan intra-articular injection, Sodium hyaluronate 10 mg/ml, 2 ml injection
Number of subjects: 100
Study 24853591 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (TX) - Tilcotil flacon, 20 mg tenoxicam/ml
Number of subjects: 100
Study 24853591 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (CS) - Diprospan flacon, 7.0 mg betamethasone/1 ml
Number of subjects: 100
Study 24853591 — intervention group
Group type: COMPARATOR
Intervention: Control group - Saline solution injected intra-articularly
Number of subjects: 100
Study 22889234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage
Number of subjects: 99
Study 22889234 — intervention group
Group type: COMPARATOR
Intervention: No cerclage
Number of subjects: 99
Study 22889234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage (in women with CL < 15 mm)
Number of subjects: 99
Study 22889234 — intervention group
Group type: COMPARATOR
Intervention: No cerclage (in women with CL < 15 mm)
Number of subjects: 99
Study 19127069 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sulphite wine
Number of subjects: 8
Study 19127069 — intervention group
Group type: COMPARATOR
Intervention: Low-sulphite wine
Number of subjects: 8
Study 17389492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) measured at 5200 m after acute exposure
Number of subjects: 76
Study 17389492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) measured at baseline and postexpedition at sea-level
Number of subjects: 76
Study 17389492 — intervention group
Group type: EXPERIMENTAL
Intervention: Central corneal thickness (CCT) measured at 5200 m
Number of subjects: 76
Study 17389492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) at altitude
Number of subjects: 76
Study 15562061 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 33
Study 15562061 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 33
Study 11495396 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS at 20 Hz for 2 seconds over 20 trains at 80% of motor threshold
Number of subjects: 20
Study 11495396 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (placebo stimulation)
Number of subjects: 20
Study 11495396 — intervention group
Group type: COMPARATOR
Intervention: Both groups (active and sham treatment)
Number of subjects: 20
Study 9422453 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Axis prosthetic foot
Number of subjects: 10
Study 9422453 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle Lite prosthetic foot
Number of subjects: 10
Study 9422453 — intervention group
Group type: EXPERIMENTAL
Intervention: Flex Foot prosthetic foot
Number of subjects: 10
Study 9422453 — intervention group
Group type: COMPARATOR
Intervention: Control group (individuals without transtibial amputations)
Number of subjects: 10
Study 7894539 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 0
Study 7894539 — intervention group
Group type: COMPARATOR
Intervention: Comparative drugs (benzodiazepines)
Number of subjects: 0
Study 3310750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous terbutaline (6 micrograms/kg, two times at an hour interval)
Number of subjects: 23
Study 3310750 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline (0.1 mg/kg, two times)
Number of subjects: 23
Study 29807126 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (cycling for 1 hour at 50% of maximum oxygen uptake)
Number of subjects: 16
Study 29807126 — intervention group
Group type: COMPARATOR
Intervention: Control (3 hours of rest)
Number of subjects: 16
Study 27272608 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-only intervention
Number of subjects: 199
Study 27272608 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (parent + teacher)
Number of subjects: 199
Study 24576432 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior vena cava filter insertion
Number of subjects: 371
Study 24576432 — intervention group
Group type: COMPARATOR
Intervention: No inferior vena cava filter insertion (control)
Number of subjects: 371
Study 22357133 — intervention group
Group type: COMPARATOR
Intervention: Maximal strength training
Number of subjects: 10
Study 20097039 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Sealer 6.0‐VT (BPS 6.0‐VT)
Number of subjects: 105
Study 20097039 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrocautery (Erbe ICC 350)
Number of subjects: 105
Study 18036807 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 1800 mg daily for 4 months
Number of subjects: 144
Study 18036807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 16899602 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 187
Study 16899602 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin + Tamoxifen
Number of subjects: 187
Study 16899602 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIX positivity in HIF-1alpha-negative tumors
Number of subjects: 187
Study 12134127 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% fenticonazole
Number of subjects: 80
Study 12134127 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% fenticonazole
Number of subjects: 80
Study 12134127 — intervention group
Group type: EXPERIMENTAL
Intervention: 100000UI nystatin
Number of subjects: 80
Study 12134127 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% ketoconazole
Number of subjects: 80
Study 10453632 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet scraping and HEPA vacuuming
Number of subjects: 6
Study 10453632 — intervention group
Group type: COMPARATOR
Intervention: Dry scraping followed by dry sweeping
Number of subjects: 6
Study 10453632 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet scraping and HEPA vacuuming with portable HEPA-filtered exhaust fan
Number of subjects: 6
Study 10453632 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 6
Study 8845325 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of medroxyprogesterone acetate (1000 mg p.o. q.d.s. for 48 h)
Number of subjects: 211
Study 8845325 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral maintenance dose of 1000 mg daily
Number of subjects: 211
Study 8845325 — intervention group
Group type: COMPARATOR
Intervention: Oral maintenance dose of 500 mg daily
Number of subjects: 211
Study 2212796 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 495086 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (20 mg t.i.d. for three days) in Study I (50 patients)
Number of subjects: 99
Study 495086 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (20 mg t.i.d. for two months) in Study II (31 patients)
Number of subjects: 99
Study 495086 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine (weekly decreasing doses for three months) in Study III (9 patients with vertigo of recent origin)
Number of subjects: 99
Study 495086 — intervention group
Group type: COMPARATOR
Intervention: Placebo (weekly decreasing doses for three months) in Study III (18 patients with vertigo of recent origin)
Number of subjects: 99
Study 30427232 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mM quinine (Bitter1)
Number of subjects: 9
Study 30427232 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mM quinine (Bitter2)
Number of subjects: 9
Study 30427232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30427232 — intervention group
Group type: COMPARATOR
Intervention: Sweet solution
Number of subjects: 9
Study 30427232 — intervention group
Group type: COMPARATOR
Intervention: Bitter1
Number of subjects: 9
Study 30427232 — intervention group
Group type: COMPARATOR
Intervention: Bitter2
Number of subjects: 9
Study 28802290 — intervention group
Group type: EXPERIMENTAL
Intervention: Encover® 400 ml/day for 8 weeks
Number of subjects: 174
Study 28802290 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (Control)
Number of subjects: 174
Study 26510186 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glucose degradation product (GDP) solution
Number of subjects: 64
Study 26510186 — intervention group
Group type: COMPARATOR
Intervention: Conventional solutions
Number of subjects: 64
Study 23968123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine partial Agonist, Aripiprazole
Number of subjects: 0
Study 20570490 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 sessions of attention shaping
Number of subjects: 29
Study 20570490 — intervention group
Group type: EXPERIMENTAL
Intervention: 1, 3, or 5 sessions of attention shaping
Number of subjects: 29
Study 20570490 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention shaping program performance
Number of subjects: 29
Study 20570490 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye tracking pre and post-tests
Number of subjects: 29
Study 19874593 — intervention group
Group type: EXPERIMENTAL
Intervention: H-Wave device stimulation (HWDS)
Number of subjects: 22
Study 19874593 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO
Number of subjects: 22
Study 17171416 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless PNL
Number of subjects: 35
Study 17171416 — intervention group
Group type: COMPARATOR
Intervention: Standard PNL
Number of subjects: 35
Study 15522378 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide sub‐Tenon's capsule injection
Number of subjects: 100
Study 15522378 — intervention group
Group type: COMPARATOR
Intervention: 1% prednisolone eyedrops
Number of subjects: 100
Study 11504661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent parathyroid hormone (PTH) administration
Number of subjects: 0
Study 9438594 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0
Study 9438594 — intervention group
Group type: COMPARATOR
Intervention: Weekly 5-fluorouracil chemotherapy
Number of subjects: 0
Study 8403669 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-impregnated methylmethacrylate beads
Number of subjects: 28
Study 8403669 — intervention group
Group type: COMPARATOR
Intervention: Systemic antibiotics alone
Number of subjects: 28
Study 2936282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium aerosol
Number of subjects: 24
Study 2936282 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 24
Study 31237313 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 574
Study 31237313 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum 1,25-dihydroxyvitamin D (1,25(OH)2D)
Number of subjects: 574
Study 31237313 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum 25(OH)D and 1,25(OH)2D
Number of subjects: 574
Study 28369940 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS1 rs1801123 C/- carriers (N=105)
Number of subjects: 1106
Study 28369940 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF1 rs2946834 T/- variant (N=280)
Number of subjects: 1106
Study 28369940 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF1 rs2946834 T/- carriers in RAS wild-type subgroup
Number of subjects: 1106
Study 26178500 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1 mg/kg for induction, maintenance 0.5 mg/kg/h)
Number of subjects: 72
Study 26178500 — intervention group
Group type: COMPARATOR
Intervention: Right beauty pyrimidine (1 mg/kg/h for 20 min, maintenance 0.3-0.7 mg/kg/h)
Number of subjects: 72
Study 26178500 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 72
Study 23465819 — intervention group
Group type: EXPERIMENTAL
Intervention: IUD insertion
Number of subjects: 120
Study 21135266 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sunscreen application
Number of subjects: 1621
Study 21135266 — intervention group
Group type: COMPARATOR
Intervention: Discretionary sunscreen application
Number of subjects: 1621
Study 19860981 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological specimen collection (blood and urine)
Number of subjects: 85
Study 16850001 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dissemination of CPGs (multifaceted educational interventions including Web-based tools to dietitians)
Number of subjects: 623
Study 16850001 — intervention group
Group type: COMPARATOR
Intervention: Passive dissemination of CPGs (mailed guidelines to dietitians)
Number of subjects: 623
Study 10874266 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic abciximab
Number of subjects: 178
Study 10874266 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic placebo
Number of subjects: 178
Study 8931526 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal coagulation of the tibial nerve
Number of subjects: 60
Study 8931526 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene ankle-foot orthosis
Number of subjects: 60
Study 8931526 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments combined
Number of subjects: 60
Study 8931526 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfortable and maximal safe walking speed
Number of subjects: 60
Study 1383520 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluid only
Number of subjects: 93
Study 1383520 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluids
Number of subjects: 93
Study 3890764 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime insulin injections
Number of subjects: 16
Study 3890764 — intervention group
Group type: COMPARATOR
Intervention: Teatime insulin injections
Number of subjects: 16
Study 3542981 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 90
Study 3542981 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 90
Study 28982804 — intervention group
Group type: EXPERIMENTAL
Intervention: autoCPAP (5‐15 mbar)
Number of subjects: 208
Study 28982804 — intervention group
Group type: COMPARATOR
Intervention: fCPAP (pressure set at the 90th percentile applied by autoCPAP during 2‐4 weeks adaptation)
Number of subjects: 208
Study 28847546 — intervention group
Group type: EXPERIMENTAL
Intervention: mAF App
Number of subjects: 209
Study 25704221 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional restoration program with forward head posture corrective exercises
Number of subjects: 154
Study 25704221 — intervention group
Group type: COMPARATOR
Intervention: Functional restoration program without forward head posture corrective exercises
Number of subjects: 154
Study 23838604 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor-associated angioedema
Number of subjects: 664
Study 23838604 — intervention group
Group type: EXPERIMENTAL
Intervention: T allele of rs500766 in PRKCQ
Number of subjects: 664
Study 23838604 — intervention group
Group type: EXPERIMENTAL
Intervention: G allele of rs2724635 in ETV6
Number of subjects: 664
Study 23838604 — intervention group
Group type: EXPERIMENTAL
Intervention: rs989692 in the gene encoding neprilysin (MME)
Number of subjects: 664
Study 21947196 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (IL-1 receptor antagonist)
Number of subjects: 46
Study 21947196 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 46
Study 18431084 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training program (aerobic, muscle strength, balance)
Number of subjects: 96
Study 18431084 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention program (individually targeted advice and group sessions)
Number of subjects: 96
Study 18431084 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of physical training and nutritional intervention
Number of subjects: 96
Study 18431084 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 16926660 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling (and placebo)
Number of subjects: 563
Study 16926660 — intervention group
Group type: COMPARATOR
Intervention: Control (no dietary counselling and placebo)
Number of subjects: 563
Study 16926660 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (no dietary counselling)
Number of subjects: 563
Study 16926660 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling and omega-3 PUFA supplementation
Number of subjects: 563
Study 12675646 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart with intensified basal NPH insulin supplementation
Number of subjects: 368
Study 12675646 — intervention group
Group type: COMPARATOR
Intervention: Human regular insulin with standard basal NPH insulin
Number of subjects: 368
Study 11123453 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoralen-ultraviolet A (PUVA) therapy
Number of subjects: 44
Study 11123453 — intervention group
Group type: COMPARATOR
Intervention: Psoralen-ultraviolet B (PUVB) therapy
Number of subjects: 44
Study 9177984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol treatment (group A)
Number of subjects: 88
Study 9177984 — intervention group
Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 88
Study 1545249 — intervention group
Group type: EXPERIMENTAL
Intervention: AT877 (30 mg, intravenous injection over 30 minutes, three times a day for 14 days)
Number of subjects: 267
Study 1545249 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, intravenous injection over 30 minutes, three times a day for 14 days)
Number of subjects: 267
Study 3893805 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 6
Study 3893805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29254398 — intervention group
Group type: EXPERIMENTAL
Intervention: Latin dance program
Number of subjects: 21
Study 29254398 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 21
Study 28634654 — intervention group
Group type: COMPARATOR
Intervention: guselkumab treatment
Number of subjects: 238
Study 26450000 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump design modifications and protocol-driven change in antiplatelet therapy
Number of subjects: 382
Study 26450000 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved blood pressure management (IBPM) protocols
Number of subjects: 382
Study 26450000 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin ≤81 mg and atrial fibrillation
Number of subjects: 382